Genetic Diagnosis in Inherited Metabolic Disorders: Why Early Detection Saves Lives

In clinical practice, many patients present with complex symptoms yet remain without a clear diagnosis for years—enduring what medicine calls the "diagnostic odyssey." For these challenging cases, the most powerful molecular diagnostic tools available are Whole Exome Sequencing (WES) and Whole Genome Sequencing (WGS).

What are WES and WGS, how do they differ, and when should clinicians order them?

What is Whole Exome Sequencing (WES)?

The human genome contains roughly 3 billion base pairs. However, only about 1% to 2% of this vast sequence directly codes for proteins—a region known as the "Exome."

Remarkably, approximately 85% of known disease-causing mutations reside within this small protein-coding fraction. WES focuses specifically on these protein-coding regions across roughly 20,000 genes, offering a cost-effective and clinically actionable diagnostic strategy.

What is Whole Genome Sequencing (WGS)?

Whole Genome Sequencing (WGS) analyzes 100% of the human genome—including both protein-coding exons and non-coding intronic, regulatory, and intergenic regions.

WGS represents the ultimate diagnostic test for identifying deep intronic variants, large structural variations (SVs), and complex copy number variations (CNVs) that may fall outside the reach of WES.

Comparing WES and WGS

The following breakdown outlines the primary clinical differences between WES and WGS:

Clinical Indications for WES or WGS

1. Unexplained Complex Phenotypes: Patients with multi-system involvement that does not fit a single classic clinical syndrome.
2. Neurodevelopmental Delays: Unexplained global developmental delay, intellectual disability, or autism spectrum disorders in pediatric patients.
3. Suspected Familial Rare Diseases: Families presenting with recurrent uncharacterized genetic conditions.
4. Congenital Anomalies: Infants born with multiple congenital malformations requiring rapid genomic clarification.

The Value of Trio-WES / Trio-WGS Analysis

When performing WES or WGS, sequencing the patient (proband) alongside both biological parents is known as Trio Analysis.

Trio sequencing provides major diagnostic advantages:

1. It immediately determines whether a variant is inherited from a parent or arose spontaneously as a de novo mutation in the child.
2. It streamlines the filtering of Variants of Uncertain Significance (VUS), boosting overall diagnostic yield by 30% to 40%.

Understanding Secondary/Incidental Findings

Because WES and WGS evaluate thousands of genes beyond the primary clinical presentation, patients can opt-in to receive reports on actionable secondary findings (e.g., medically manageable hereditary cancer or cardiac predisposition genes listed by the ACMG 73 framework).

To learn more about resolving complex clinical cases with advanced WES and WGS services, visit Nucleus Genetics.